Targeting inflammation in the treatment of type 2 diabetes: Time to start

Nature Reviews Drug Discovery

Volumn 13, Issue 6, 2014, Pages 465-476

  Donath, Marc Y ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AC 201; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTIINFLAMMATORY AGENT; CANAKINUMAB; CCX 140B; DIACEREIN; ETANERCEPT; GEVOKIZUMAB; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCOSE; INCRETIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; LENERCEPT; LY 2189102; METFORMIN; MONOCLONAL ANTIBODY MABP1; PIOGLITAZONE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIMONABANT; SALSALATE; SULFONYLUREA DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CHOLESTEROL BLOOD LEVEL; DIABETOGENESIS; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNOMODULATION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INJECTION SITE REACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MENTAL DISEASE; METABOLIC STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; WEIGHT GAIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY;

EID: 84901920026     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4275     Document Type: Review

References (151)

1. Cerasi, E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 38, 992-997 (1995).
2. Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840-846 (2006).
3. Bonner-Weir, S. Islet growth and development in the adult. J. Mol. Endocrinol. 24, 297-302 (2000).
4. Kahn, B. B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 92, 593-596 (1998).
5. Robertson, R. P., Harmon, J., Tran, P. O. & Poitout, V. β-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 (Suppl. 1), 119-124 (2004).
6. Weir, G. C. & Bonner-Weir, S. Five stages of evolving β-cell dysfunction during progression to diabetes. Diabetes 53 (Suppl. 3), 16-21 (2004).
7. Prentki, M. & Nolan, C. J. Islet β cell failure in type 2 diabetes. J. Clin. Invest. 116, 1802-1812 (2006).
8. Hull, R. L., Westermark, G. T., Westermark, P. & Kahn, S. E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 3629-3643 (2004).
9. Harding, H. P. & Ron, D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 51 (Suppl. 3), 455-461 (2002).
10. Hotamisligil, G. S. & Erbay, E. Nutrient sensing and inflammation in metabolic diseases. Nature Rev. Immunol. 8, 923-934 (2008).
11. Donath, M. Y., Storling, J., Maedler, K. & Mandrup-Poulsen, T. Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. 81, 455-470 (2003).
12. Ehses, J. A., Ellingsgaard, H., Boni-Schnetzler, M. & Donath, M. Y. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch. Physiol. Biochem. 115, 240-247 (2009).
13. Westwell-Roper, C. Y., Ehses, J. A. & Verchere, C. B. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and β cell dysfunction. Diabetes 63, 1698-1711 (2014).
14. Westwell-Roper, C. et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J. Immunol. 187, 2755-2765 (2011).
15. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature Immunol. 11, 897-904 (2010).
16. Jourdan, T. et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates β cell loss in type 2 diabetes. Nature Med. 19, 1132-1140 (2013).
17. Oslowski, C. M. et al. Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab. 16, 265-273 (2012).
18. Lerner, A. G. et al. IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab. 16, 250-264 (2012).
19. Maedler, K. et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851-860 (2002).
20. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunol. 11, 136-140 (2010).
21. Boni-Schnetzler, M. et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150, 5218-5229 (2009).
22. Pal, D. et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nature Med. 18, 1279-1285 (2012).
23. Maedler, K. et al. FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication. Proc. Natl Acad. Sci. USA 99, 8236-8241 (2002).
24. Ehses, J. A. et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56, 2356-2370 (2007).
25. Richardson, S. J., Willcox, A., Bone, A. J., Foulis, A. K. & Morgan, N. G. Islet-associated macrophages in type 2 diabetes. Diabetologia 52, 1686-1688 (2009).
26. Butcher, M. J. et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. Diabetologia 57, 491-501 (2014).
27. Boni-Schnetzler, M. et al. Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93, 4065-4074 (2008).
28. Di Marzo, V. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825 (2001).
29. Osei-Hyiaman, D. et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115, 1298-1305 (2005).
30. Bendtzen, K. et al. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232, 1545-1547 (1986).
31. Mandrup-Poulsen, T. et al. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 29, 63-67 (1986).
32. Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900-917 (2010).
33. Martinez, J., Verbist, K., Wang, R. & Green, D. R. The relationship between metabolism and the autophagy machinery during the innate immune response. Cell Metab.17, 895-900 (2013).
34. Skurk, T., Alberti-Huber, C., Herder, C. & Hauner, H. Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab. 92, 1023-1033 (2007).
35. Stienstra, R. et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell. Metab. 12, 593-605 (2010).
36. Koenen, T. B. et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1β transcription in human adipose tissue. Diabetes 60, 517-524 (2011).
37. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature Immunol. 12, 408-415 (2011).
38. Cinti, S. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347-2355 (2005).
39. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003).
40. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
41. Prieur, X. et al. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 60, 797-809 (2011).
42. Ye, J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes. 33, 54-66 (2009).
43. Cox, L. M. & Blaser, M. J. Pathways in microbe-induced obesity. Cell Metab. 17, 883-894 (2013).
44. Ley, R. E. et al. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102, 11070-11075 (2005).
45. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
46. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
47. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007).
48. Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481 (2008).
49. Nguyen, M. T. et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 35279-35292 (2007).
50. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nature Med. 17, 179-188 (2011)
51. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
52. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
53. Ofei, F., Hurel, S., Newkirk, J., Sopwith, M. & Taylor, R. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45, 881-885 (1996).
54. Paquot, N., Castillo, M. J., Lefebvre, P. J. & Scheen, A. J. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85, 1316-1319 (2000).
55. Dominguez, H. et al. Metabolic and vascular effects of tumor necrosis factor-α blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42, 517-525 (2005).
56. Bernstein, L. E., Berry, J., Kim, S., Canavan, B. & Grinspoon, S. K. Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 166, 902-908 (2006).
57. Stanley, T. L. et al. TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J. Clin. Endocrinol. Metab. 96, E146-E150 (2011).
58. Yazdani-Biuki, B. et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-α antibody infliximab. Eur. J. Clin. Invest. 34, 641-642 (2004).
59. Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N. & Drosos, A. A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64, 765-766 (2005).
60. Yazdani-Biuki, B. et al. Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-α antibody infliximab: a case observation. Diabetes Care 29, 1712-1713 (2006).
61. Gonzalez-Gay, M. A. et al. Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24, 83-86 (2006).
62. Huvers, F. C., Popa, C., Netea, M. G., van den Hoogen, F. H. & Tack, C. J. Improved insulin sensitivity by anti-TNFα antibody treatment in patients with rheumatic diseases. Ann. Rheum. Dis. 66, 558-559 (2007).
63. Marra, M. et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int. J. Immunopathol. Pharmacol. 20, 731-736 (2007).
64. Timper, K., Hruz, P., Beglinger, C. & Donath, M. Y. Infliximab in the treatment of Crohn disease and type 1 diabetes. Diabetes Care 36, e90-91 (2013).
65. Solomon, D. H. et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305, 2525-2531 (2011).
66. Antohe, J. L. et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res. 64, 215-221 (2012).
67. Larsen, C. M. et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663-1668 (2009).
68. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
69. van Asseldonk, E. J. et al. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 2119-2126 (2011).
70. van Asseldonk, E. J. P. et al. One week of treatment with the IL-1 receptor antagonist anakinra improves insulin sensitivity in patients with type 1 diabetes mellitus: results from a clinical trial. In: 48th Annual Meeting of the European Association for the Study of Diabetes [online], http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2978 & sKey= bfb594eb-2951-4058-a15c-558a22013054 & cKey =65b472ec-2f9d-4cc6-8b1d- 5144d103d937 & mKey=2dbfcaf7-1539-42d5-8dda-0a94abb089e8 Abstract 560 (2012).
71. van Popper, P. C. M., Van Asseldonk, E. V. A., Netea, M. G. & Tack, C. J. The interleukin-1 receptor antagonist anakinra improves (3 cell function in subjects with impaired glucose tolerance. In: 49th Annual Meeting of the European Association for the Study of Diabetes [online], http://www. easdvirtualmeeting.org/resources/4273 Abstract 739 (2013).
72. Cavelti-Weder, C. et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654-1662 (2012).
73. Hensen, J., Howard, C. P., Walter, V. & Thuren, T Impact of interleukin-1 (3 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 39, 524-531 (2013).
74. Rissanen, A. et al., Howard, C. P., Botha, J., Thuren, T & for the Global Investigators. Effect of anti-IL-1 p antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes. Metab. 14, 1088-1096 (2012).
75. Sloan-Lancaster, J. et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1 p antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239-2246 (2013).
76. Yuan, M. et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkp. Science 293, 1673-1677 (2001).
77. Fleischman, A., Shoelson, S. E., Bernier, R. & Goldfine, A. B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31, 289-294 (2008).
78. Goldfine, A. B. et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 1, 36-43 (2008).
79. Koska, J. et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 52, 385-393 (2009).
80. Goldfine, A. B. et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346-357 (2010).
81. Goldfine, A. B. et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann. Intern.Med. 159, 1-12 (2013).
82. Goldfine, A. B. et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56, 714-723 (2013).
83. Faghihimani, E. et al. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 50, 537-543 (2013).
84. Ramos-Zavala, M. G. et al. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care 34, 1591-1594 (2011).
85. Freigang, S. et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1 a and sterile vascular inflammation in atherosclerosis. Nature Immunol. 14, 1045-1053 (2013).
86. Timper, K. et al. IL-1 a antagonism in type 2 diabetes. In: 95th Annual Meeting of the Endocrine Society [online], https://endo.confex.com/endo/ 2013endo/webprogram/Paper7270.html Abstract SUN-856 (2013).
87. Sartipy, P. & Loskutoff, D. J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl Acad. Sci. USA 100, 7265-7270 (2003).
88. Kanda, H. et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494-1505 (2006).
89. Weisberg, S. P. et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 116, 115-124 (2006).
90. Hanefeld, M. et al. Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial. J. Diabetes Metab. http://dx.doi. org/10.4172/2155-6156.1000225 (2012).
91. Pedersen, B. K. & Febbraio, M. A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 88, 1379-1406 (2008).
92. Pedersen, B. K. & Febbraio, M. A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Rev. Endocrinol. 8, 457-465 (2012).
93. Carey, A. L. et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55, 2688-2697 (2006).
94. Jansson, J. O. & Wallenius, V. Point-counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 821; author reply 825 (2007)
95. Mooney, R. A. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 816-818; discussion 818-819 (2007).
96. Pedersen, B. K. & Febbraio, M. A. Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 814-816 (2007).
97. Sabio, G. et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322, 1539-1543 (2008).
98. Weigert, C., Lehmann, R. & Schleicher, E. D. Point-counterpoint: interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 820-821; author reply 825 (2007).
99. Wunderlich, F. T. et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 12, 237-249 (2010).
100. Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and α cells. Nature Med. 17, 1481-1489 (2011).
101. Lazar, M. A. How obesity causes diabetes: not a tall tale. Science 307, 373-375 (2005).
102. Rose-John, S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8, 1237-1247 (2012).
103. Imai, Y. et al. Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes Obes. Metab. 15 (Suppl. 3), 117-129 (2013).
104. Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253-295 (2010).
105. Misawa, T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nature Immunol. 14, 454-460 (2013).
106. Donath, M. Y. When metabolism met immunology. Nature Immunol. 14, 421-422 (2013).
107. Biason-Lauber, A. et al. Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell Metab. 17, 448-455 (2013).
108. + intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice. Cell Metab. 14, 528-536 (2011).
109. + metabolism and SIRT1 activity. Nature 458, 1056-1060 (2009).
110. + precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838-847 (2012).
111. Altmeyer, M. & Hottiger, M. O. Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging. Aging 1, 458-469 (2009).
112. Isoda, K. et al. Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 26, 611-617 (2006).
113. Lee, H. M. et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62, 194-204 (2013).
114. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
115. Jiang, C., Ting, A. T. & Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86 (1998).
116. Diaz-Delfin, J., Morales, M. & Caelles, C. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor γ by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 56, 1865-1871 (2007).
117. Vallerie, S. N. & Hotamisligil, G. S. The role of JNK proteins in metabolism. Sci. Transl. Med. 2, 60rv65 (2010).
118. Ferdaoussi, M. et al. Exendin-4 protects β-cells from interleukin-1β-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 57, 1205-1215 (2008).
119. Pugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G. & Pugazhenthi, S. Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia 53, 2357-2368 (2010).
120. Omar, B. A. et al. Enhanced β cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia 56, 1752-1760 (2013).
121. Chaudhuri, A. et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198-207 (2012).
122. Makdissi, A. et al. Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 97, 3333-3341 (2012).
123. Feldman, M., Jialal, I., Devaraj, S. & Cryer, B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J. Am. Coll. Cardiol. 37, 2036-2041 (2001).
124. Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. & Braunwald, E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100, 230-235 (1999).
125. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
126. Jialal, I., Miguelino, E., Griffen, S. C. & Devaraj, S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 92, 3136-3140 (2007).
127. Montero, M. T. et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153, 303-313 (2000).
128. Coward, W. R., Marei, A., Yang, A., Vasa-Nicotera, M. M. & Chow, S. C. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J. Immunol. 176, 5284-5292 (2006).
129. Kuijk, L. M. et al. HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 112, 3563-3573 (2008).
130. Kuijk, L. M. et al. Statin synergizes with LPS to induce IL-1β release by THP-1 cells through activation of caspase-1. Mol. Immunol. 45, 2158-2165 (2008).
131. Mandey, S. H., Kuijk, L. M., Frenkel, J. & Waterham, H. R. A role for geranylgeranylation in interleukin-1β secretion. Arthritis Rheum. 54, 3690-3695 (2006).
132. Liao, Y. H. et al. HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation. J. Leukoc. Biol. 93, 289-299 (2013).
133. Sattar, N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742 (2010).
134. Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I. & Cooper, M. E. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 23, 463-473 (2005).
135. van der Zijl, N. J., Moors, C. C., Goossens, G. H., Blaak, E. E. & Diamant, M. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms. Diabetes Obes. Metab. 14, 586-595 (2012).
136. Fischer, E. et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J. Clin. Endocrinol. Metab. 98, 2513-2520 (2013).
137. Fliser, D. et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110, 1103-1107 (2004).
138. Manabe, S., Okura, T., Watanabe, S., Fukuoka, T. & Higaki, J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J. Cardiovasc. Pharmacol. 46, 735-739 (2005).
139. Pavlatou, M. G. et al. Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation. Eur. J. Clin. Invest. 41, 652-658 (2011).
140. Garcia, G. E. ANG II receptor antagonists as modulators of macrophages polarization. Am. J. Physiol. Renal Physiol. 298, F868-F869 (2010).
141. Fujisaka, S. et al. Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology 152, 1789-1799 (2011).
142. Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380, 475-483 (2012).
143. Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317-1326 (2013).
144. Mirza, R. E., Fang, M. M., Ennis, W. J. & Koh, T. J. Blocking interleukin-1β induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes. Diabetes 62, 2579-2587 (2013).
145. Dinarello, C. A., Simon, A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Rev. Drug Discov. 11, 633-652 (2012).
146. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
147. Dinarello, C. A. How interleukin-1β induces gouty arthritis. Arthritis Rheum. 62, 3140-3144 (2010).
148. Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71, 1839-1848 (2012).
149. Yeung, H. et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 149, 1173-1179 (2013).
150. Libby, P., Ridker, P. M., Hansson, G. K. & Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll.Cardiol. 54, 2129-2138 (2009).
151. Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597-605 (2011).